Tilray TLRY Stock Analysis And why TLRY stock may be stuck

Eisai and Biogen’s subcutaneous Leqembi set for FDA review – Pharmaceutical Technology

Eisai and Biogen’s antibody is currently infused every two weeks at hospitals and dedicated infusion sites. Image credit: Shutterstock/ AtlasStudio. Eisai and Biogen are one

January 14, 2025

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris 01-Jul-2024 /

July 2, 2024

SIGA’s gains approval in Japan for orthopoxvirus treatment therapy

The Phase I trial of the therapy with 20 healthy subjects indicated no drug-related serious adverse events. Credit: Mongkolchon Akesin/Shutterstock. SIGA Technologies has gained Japanese

January 3, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.